Other languages AxoGen, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
5.79 ^USD	-1.53%		-12.67%	-15.23%

05-02	Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02	Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M	MT

AxoGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02
Axogen, Inc. Provides Revenue Guidance for the Year 2024	05-02
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix	04-29
Axogen Insider Sold Shares Worth $319,891, According to a Recent SEC Filing	03-08
AxoGen, Inc. Announces Executive Changes	03-08
AxoGen Files $100 Million Mixed-Securities Shelf	03-06
AxoGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024	03-05
Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study	01-18
Axogen Expects Higher Q4 Revenue; CEO Plans to Retire	01-04
AxoGen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023	01-04
AxoGen, Inc. Revises Revenue Guidance for the Full Year of 2023	01-04
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025	01-04
Axogen, Inc. Announces Plans to Retirement of Karen Zaderej as President, Effective January 2025	01-04
AxoGen, Inc. Announces Executive Changes	01-04
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors	12-26
AxoGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
AXOGEN INC - CONTINUES TO EXPECT GROSS MARGIN FOR FULL YEAR 2023…	11-07
Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023	11-07
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector	23-09-05

No results for this search